Cyberounds Logo
August 03, 2020 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
Gene Therapy for Monogenic Diseases
CME credit is no longer available for this conference.
Matthew H. Porteus, M.D., Ph.D.

Dr. Porteus is Assistant Professor of Pediatrics, Graduate School of Biomedical Sciences, University of Texas Southwestern Medical School, Dallas, Texas. Within the past 12 months, Dr. Porteus no commercial conflicts of interest.

Release Date: 09/10/2006
Termination Date: 09/10/2009

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Describe the different types of viral vectors that are being used in gene therapy
  • Summarize the successes and setbacks in the recent clinical trials for gene therapy
  • Describe the future directions of gene therapy research to improve the safety of gene therapy.

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Please click below to accept the terms of this CME activity